AltrixBio, Inc.

AltrixBio, Inc. , based in the US, develops innovative oral therapies targeting metabolic conditions, including type 2 diabetes, through groundbreaking solutions that mimic the effects of bariatric surgery. Founded in 2019 and headquartered in Lowell, US, AltrixBio, Inc. specializes in oral therapies for metabolic disorders.

The company successfully raised USD 5. 00 mn in Series A funding on April 30, 2025, aimed at advancing its oral therapy for type 2 diabetes. The founder has a history in health technology, although specific previous ventures are not disclosed. AltrixBio's core product offering is LuCI™ (Luminal Coating of the Intestine), designed to replicate the metabolic benefits of bariatric surgery in a non-surgical, oral format.

This innovative therapy provides a local and transient coating to the stomach and proximal intestine, triggering hormonal cascades similar to those experienced after bariatric procedures. LuCI™ aims to improve insulin sensitivity, suppress hunger, and enhance satiety hormones to achieve better glycemic control and promote weight loss. This product targets individuals with type 2 diabetes (T2D) and obesity, addressing a significant and growing health crisis. AltrixBio's products are positioned to serve markets in North America, Europe, and Asia, catering to patients who require effective diabetes management solutions without the complexities associated with traditional therapies.

AltrixBio generates revenue primarily through the commercialization of its flagship product, LuCI™, positioned as a "Surgery in a Pill®. " The company is expected to establish partnerships with healthcare providers and pharmaceutical wholesalers to facilitate access to its therapy, focusing on a B2B model that enhances distribution capabilities. Transactions are structured around direct sales and institutional partnerships, enabling healthcare systems to incorporate LuCI™ into their treatment regimens for diabetes and obesity management. Pricing strategies for LuCI™ will reflect its positioning as a novel therapeutic solution, with anticipated plans for reimbursement arrangements to support patient access.

The company aims to leverage its patent-protected technology to build long-term relationships within the medical community and expand its market presence. In April 30 2025, AltrixBio Inc. raised USD 5. 00 mn in Series A funding from unspecified investors.

The funding will support the clinical development of its oral therapy for type 2 diabetes and related metabolic conditions. Future plans include launching additional products aimed at enhancing diabetes management and expanding market reach into new regions, including targeted initiatives in Europe and Asia by 2026.